Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that director Jack E. Stover received a grant of stock options covering 33,435 shares of common stock. The options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan. They will vest 100% on the first anniversary of the March 8, 2026 grant date, giving Stover the right to buy the full amount after one year if he chooses to exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STOVER JACK E

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		33,435		03/08/2027(1)	03/08/2036	Common Stock	33,435	$0	33,435	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Jack E. Stover	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) disclose for Jack E. Stover?

Traws Pharma disclosed that director Jack E. Stover received a grant of stock options for 33,435 shares. These options give him the right to buy common stock at a fixed exercise price once they vest after one year.

How many stock options did Jack E. Stover receive from Traws Pharma (TRAW)?

Jack E. Stover received stock options for 33,435 underlying shares of Traws Pharma common stock. All of these options were granted in a single award and represent his reported derivative holdings following the transaction.

What is the exercise price of Jack E. Stover’s Traws Pharma (TRAW) stock options?

The exercise price of Jack E. Stover’s stock options is $1.6000 per share. This means he can buy Traws Pharma common stock at that price once the options vest, regardless of the market price at that time.

When do Jack E. Stover’s Traws Pharma (TRAW) stock options vest and expire?

Jack E. Stover’s stock options vest 100% on the first anniversary of the grant date, March 8, 2027. They expire on March 8, 2036, giving him nearly nine years after vesting to decide whether to exercise.

Under which plan were the Traws Pharma (TRAW) stock options granted to Jack E. Stover?

The stock options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated to the grant date. This plan is overseen by the compensation committee, which is composed of independent directors.

Is Jack E. Stover’s Traws Pharma (TRAW) option grant an open-market purchase?

No, Jack E. Stover’s transaction is a compensation-related grant, not an open-market purchase. The options were awarded by the company’s compensation committee at no purchase price, with value realized only if he later exercises at $1.6000 per share.